Royal Bank of Canada’s Theriva Biologics TOVX Stock Holding History

Royal Bank of Canada’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Buy	+1	New	–	﹤0.01%	7696
2024 Q3	–	Hold	0	–	–	–	7444
2024 Q2	–	Hold	0	–	–	–	7537
2024 Q1	–	Hold	0	–	–	–	7597
2023 Q4	–	Hold	0	–	–	–	7589
2023 Q3	–	Hold	0	–	–	–	7602
2023 Q2	–	Hold	0	–	–	–	7670
2023 Q1	–	Hold	0	–	–	–	7478
2022 Q4	–	Hold	0	–	–	–	7726
2022 Q3	–	Hold	0	–	–	–	7865
2022 Q2	–	Hold	0	–	–	–	7717
2022 Q1	–	Sell	-40	Closed	-$2.73K	–	8017
2021 Q4	$3K	Buy	40 +39	+3,900%	+$3.68K	﹤0.01%	7348
2021 Q3	$0	Buy	+1	New	+$124	﹤0.01%	7876
2021 Q2	–	Hold	0	–	–	–	7691
2021 Q1	–	Hold	0	–	–	–	7701
2020 Q4	–	Hold	0	–	–	–	7291
2020 Q3	–	Hold	0	–	–	–	6932
2020 Q2	–	Sell	-1	Closed	-$95	–	6908
2020 Q1	$0	Buy	+1	New	+$114	﹤0.01%	7023
2019 Q4	–	Hold	0	–	–	–	7119
2019 Q3	–	Hold	0	–	–	–	7115
2019 Q2	–	Hold	0	–	–	–	7181
2019 Q1	–	Sell	-1	Closed	-$166	–	7098
2018 Q4	$0	Sell	1 -1	-50%	-$237	﹤0.01%	7111
2018 Q3	$1K	Sell	2 -1	-33%	-$1.1K	﹤0.01%	6624
2018 Q2	$6K	Buy	3 +2	+200%	+$4.59K	﹤0.01%	5998
2018 Q1	$4K	Sell	1 -1	-50%	-$3.8K	﹤0.01%	6002
2017 Q4	$9K	Sell	2 -1	-33%	-$6.25K	﹤0.01%	5906
2017 Q3	$21K	Hold	3	–	–	﹤0.01%	5932
2017 Q2	$12K	Hold	3	–	–	﹤0.01%	5738
2017 Q1	$20K	Sell	3 -2	-40%	-$14K	﹤0.01%	5625
2016 Q4	$33K	Hold	5	–	–	﹤0.01%	5496
2016 Q3	$74K	Hold	5	–	–	﹤0.01%	4965
2016 Q2	$77K	Buy	5 +3	+150%	+$56.5K	﹤0.01%	4899
2016 Q1	$47K	Hold	2	–	–	﹤0.01%	5159
2015 Q4	$34K	Buy	+2	New	+$42.3K	﹤0.01%	5503
2015 Q3	–	Hold	0	–	–	–	6050
2015 Q2	–	Sell	-1	Closed	-$11K	–	6715
2015 Q1	$11K	Buy	+1	New	+$17.9K	﹤0.01%	5551

Other funds holding TOVX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Royal Bank of Canada's TOVX Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Theriva Biologics (TOVX) in Q1 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7696 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in TOVX as recently as Q4 2021.

Royal Bank of Canada first reported a position in TOVX in Q1 2015 and has held it in 18 quarters since. The position peaked at $77K in Q2 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

Royal Bank of Canada held 1 share of Theriva Biologics worth $0 as of Q1 2026.
Theriva Biologics was a new Royal Bank of Canada position in Q1 2026.
Theriva Biologics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7696 holding.
Royal Bank of Canada first reported a position in Theriva Biologics in Q1 2015 and has held it in 18 quarters since.
Royal Bank of Canada's Theriva Biologics position peaked at $77K in Q2 2016.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.